On December 30, the board of CH BIOTECH SER (08037) officially announced its plan to issue a 4-year, USD 35 million (approximately HKD 272 million) convertible bond through a special mandate to Fu Ce Holdings, controlled by the renowned investor Mr. Gong Hongjia. This transaction is far more than a simple financial fundraising exercise. From a capital markets perspective, the industrial confidence signal and resource integration value it releases far exceed the capital injection itself, marking a pivotal moment where CH BIOTECH SER welcomes a strategic-level partner at a critical development stage, injecting substantial momentum for the company's core business upgrades and its full industry chain layout.

Mr. Gong Hongjia, a benchmark figure in China's investment and industrial sectors, has created numerous industry-defining cases based on decades of deep accumulation in healthcare and telecommunications technology. Ranked 29th on the 2022 Forbes China Rich List, he is not only renowned for his precise industrial insights but also widely praised for his philosophy of empowering companies' long-term development with "patient capital." In his investment career, his most well-known achievement is the angel investment and co-founding of the world-leading security company Hikvision (002415.SZ)—a case that has become one of the most successful angel investment models in China, demonstrating his exceptional ability to identify high-quality sectors and accompany companies through their growth. His footprint in the healthcare sector is equally profound and precise: serving as Chairman and a major shareholder of Zhongyuan Union Cell & Gene Engineering (600645.SH), a leader in stem cell preparation, testing, and storage in China, while also controlling Heyuan Bio, which focuses on cell therapy. These two core investments align highly with CH BIOTECH SER's "three pillars" strategy of "Testing Services + CAR-T Cell Therapy + BNCT Boron Neutron Capture Therapy," particularly in the iteration of testing technologies and the industrial application of cell therapies, where resource complementarity is extremely strong, laying a solid foundation for deep future collaboration. The entry of a heavyweight industrial investor at this juncture essentially signifies deep recognition of CH BIOTECH SER's business layout, development stage, and core technological value, forming a golden combination of "critical stage + key investor + key business."

The core focus of Mr. Gong Hongjia's strategic investment lies in CH BIOTECH SER's forward-looking layout and breakthrough progress in the field of BNCT. As a globally advanced new cancer radiotherapy technology, BNCT has demonstrated remarkable curative potential in clinical applications due to its core advantages of "precision targeting, significant efficacy, and minimal side effects," offering new hope for advanced cancer patients and establishing itself as a key track in the global biomedical field. The establishment and advancement of Pengbo (Hainan) Boron Neutron Hospital under CH BIOTECH SER is a crucial move to capture the high ground in the BNCT industry. Founded in 2022 and located in the Boao Lecheng International Medical Tourism Pilot Zone, an area rich with policy incentives, the hospital specializes in providing high-end BNCT medical services. It has successfully introduced the world's only approved, most advanced BNCT cancer treatment system and completed beam commissioning in November 2025, with patient consultations expected to commence formally in the first quarter of 2026. Previously, the pace of the company's BNCT business deployment was constrained by funding bottlenecks; however, with the injection of Mr. Gong's strategic capital and the empowerment from his accumulated industrial resources, channel networks, and management experience in the healthcare sector, these financial constraints will be effectively resolved, accelerating the clinical promotion, market penetration, and integration of the upstream and downstream BNCT industry chain. Furthermore, the mature investments in testing technology and cell therapy held by Mr. Gong's controlled companies can form a full-process synergy of "diagnosis-treatment-rehabilitation" with BNCT therapy, further amplifying the technology's value and commercial potential, enabling this revolutionary treatment to benefit a wider population of cancer patients more rapidly.

The finalization of this strategic cooperation coincides with a golden period for the BNCT industry, characterized by a dual explosion of policy support and market demand. From a policy perspective, the National Medical Products Administration has included BNCT-related projects in its priority review channel, significantly shortening the policy cycle for technology implementation; more notably, BNCT technology has been included for the first time in the "15th Five-Year Plan," signifying its elevation to a strategically emerging industry with national key support, providing clear policy direction and resource guarantees for industry development. From a market perspective, with the continuous rise in cancer incidence rates and the increasing urgency for precision treatments among patients, BNCT, as an innovative treatment option with curative potential, boasts an extremely broad market space. Currently, domestic enterprises and medical institutions are accelerating their layouts in the BNCT industry, with a competitive landscape gradually forming and development entering a fast lane. CH BIOTECH SER, leveraging its first-mover advantage in the Boao Pilot Zone, globally leading equipment configuration, and imminent clinical services, has built significant industry barriers; Mr. Gong Hongjia's strategic entry will further strengthen the company's core competitiveness in capital, resources, and industrial synergy, helping it seize the initiative in the full BNCT industry chain layout and consolidate its leading industry position.

The introduction of Mr. Gong Hongjia as a strategic investor marks a milestone event in the development history of CH BIOTECH SER. This collaboration is not merely a capital supplement but a deep binding of industrial capital with a high-quality sector, representing a two-way empowerment between "patient capital" and technological innovation. With the arrival of strategic funds, the integration of industrial resources, and the formal operation of the BNCT hospital, CH BIOTECH SER will effectively break through previous development bottlenecks and fully embark on a phase of secondary growth. Looking ahead, against a backdrop of continuously released policy dividends and rapidly growing market demand, CH BIOTECH SER will focus on BNCT technology as its core, relying on the synergistic effects with Mr. Gong's affiliated enterprises to deepen its "three pillars" strategic layout and accelerate the processes of technology industrialization, service scaling, and industry chain integration. There is good reason to believe that this strategic cooperation will propel CH BIOTECH SER towards value reconfiguration and leapfrog development, creating long-term, stable returns for investors and making significant contributions to technological advancement and patient welfare in China's cancer treatment field. The future developments are highly anticipated.